Why hasn't neuroprotection worked in Parkinson's disease?

作者信息

Kieburtz Karl, Ravina Bernard

机构信息

University of Rochester Medical Center, Rochester, NY, USA.

出版信息

Nat Clin Pract Neurol. 2007 May;3(5):240-1. doi: 10.1038/ncpneuro0491.

DOI:10.1038/ncpneuro0491

PMID:17479072

Abstract

摘要

相似文献

Why hasn't neuroprotection worked in Parkinson's disease?

Nat Clin Pract Neurol. 2007 May;3(5):240-1. doi: 10.1038/ncpneuro0491.

I can't get no satisfaction: still no neuroprotection for Parkinson disease.

Neurology. 2007 Oct 9;69(15):1476-7. doi: 10.1212/01.wnl.0000277645.60799.0e.

Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.

Adv Neurol. 1999;80:265-9.

Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies.

Adv Neurol. 1999;80:219-25.

Neuroprotection in Parkinson's disease: an elusive goal.

Semin Neurol. 2007 Apr;27(2):106-12. doi: 10.1055/s-2007-971168.

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68.

Designing neuroprotection trials in Parkinson's disease.

Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. doi: 10.1002/ana.10484.

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.

Biochem Pharmacol. 2006 Nov 15;72(10):1197-206. doi: 10.1016/j.bcp.2006.06.031. Epub 2006 Aug 9.

Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.

Adv Neurol. 2001;86:115-24.

Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease.

J Neurosci Res. 2008 Dec;86(16):3622-34. doi: 10.1002/jnr.21805.

引用本文的文献

Models of α-synuclein aggregation in Parkinson's disease.

Acta Neuropathol Commun. 2014 Dec 13;2:176. doi: 10.1186/s40478-014-0176-9.

Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Front Neurol. 2013 Jan 21;3:187. doi: 10.3389/fneur.2012.00187. eCollection 2012.

The bad, the good, and the ugly about oxidative stress.

Oxid Med Cell Longev. 2012;2012:163913. doi: 10.1155/2012/163913. Epub 2012 Apr 26.

Treatment of Essential Tremor: Are there Issues We are Overlooking?

Front Neurol. 2012 Jan 13;2:91. doi: 10.3389/fneur.2011.00091. eCollection 2011.

Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Brain. 2011 Jul;134(Pt 7):2057-73. doi: 10.1093/brain/awr137.

Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Ther Adv Neurol Disord. 2008 Nov;1(3):167-79. doi: 10.1177/1756285608097775.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验